full-versus-sub-regional-quantification-amyloid-beta-load-on-mouse

Full- versus Sub-Regional Quantification of Amyloid-Beta Load on Mouse Brain Sections

Extracellular accumulation of amyloid-beta (A&#946;) plaques is one of the major pathological hallmarks of Alzheimer's disease (AD), and is the target of ...

Claremont McKenna College

Tumor necrosis factor-α (TNF-α) plays a central role in Alzheimer's disease (AD) pathology, making biologic TNF-α inhibitors (TNFIs), including etanercept, viable therapeutics for AD. The protective effects of biologic TNFIs on AD hallmark pathology (Aβ deposition and tau pathology) have been demonstrated. However, the effects of biologic TNFIs on Aβ-independent tau pathology have not been reported. Existing biologic TNFIs do not cross the blood-brain barrier (BBB), therefore we engineered a BBB-penetrating biologic TNFI by fusing the extracellular domain of the type-II human TNF-α receptor (TNFR) to a transferrin receptor antibody (TfRMAb) that ferries the TNFR into the brain via receptor-mediated transcytosis. The present study aimed to investigate the effects of TfRMAb-TNFR (BBB-penetrating TNFI) and etanercept (non-BBB-penetrating TNFI) in the PS19 transgenic mouse model of tauopathy.

Matthew Choi

Keck Science Department

Claremont McKenna College

Full- versus Sub-Regional Quantification of Amyloid-Beta Load on Mouse Brain Sections

Matthew Choi

.css-o250i3{font-size:18px;font-family:Open Sans,sans-serif;line-height:21.6px;}Keck Science Department

Claremont McKenna College

Full- versus Sub-Regional Quantification of Amyloid-Beta Load on Mouse Brain Sections

Keck Science Department